

## Bangladesh Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Bangladesh			
<b>2. Grant number:</b> 18-BGD-04a-X / 1718-BGD-04a-A / 08-BGD-08b-Y			
<b>3. Date of Decision Letter:</b> 21 December 2017			
<b>4. Date of the Partnership Framework Agreement:</b> 24 June 2013			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2009 - 2018			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)			
	2009-2017	2018	Total <sup>2</sup>
Programme Budget (US\$)	235,012,750 <sup>3</sup>	12,721,000	247,733,750
<b>Fragility, Emergencies and Refugees Policy (Gavi supported)</b>			
	2017	2018	Total <sup>4</sup>
Programme Budget (US\$)	455,500	139,500	595,000
<b>10. Vaccine introduction grant (in US\$):</b> A VIG in the amount of US\$1,287,000 was disbursed on 7 August 2008.			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>5</sup>			
Type of supplies to be purchased with Gavi funds in each year	2009-2017	2018	
Number of Pentavalent vaccines doses		10,971,200	
Annual Amounts (US\$)	235,012,750 <sup>6</sup>	12,721,000	
<b>Fragility, Emergencies and Refugees Policy (Gavi supported)</b>			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>5</sup> This is the amount that Gavi has approved.

<sup>6</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Type of supplies to be purchased with Gavi funds in each year	2017	2018
Number of Pentavalent vaccines doses	392,700	120,200
Annual Amounts (US\$)	455,500	139,500
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>13. Self-procurement:</b> Not applicable		
<p><b>14. Co-financing obligations:</b> Reference code: 18-BGD-04a-X-C</p> <p>According to the co-financing policy, Bangladesh falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>		
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>2018</b>	
Number of vaccine doses	867,700	
Number of AD syringes	909,200	
Number of safety boxes	10,025	
Value of vaccine doses (US\$)	937,065	
Total co-financing payments (US\$) (including freight)	1,047,500	
<p><b>Co-financing obligations for refugee population:</b> Reference code: 1718-BGD-04a-A-C</p> <p>According to the co-financing policy, Bangladesh falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>		
<b>Type of supplies to be purchased with Country funds in each year</b>	<b>2017</b>	<b>2018</b>
Number of vaccine doses	26,800	9,700
Number of AD syringes	28,300	10,100
Number of safety boxes	325	125
Value of vaccine doses (US\$)	28,851	10,464
Total co-financing payments (US\$) (including freight)	32,500	12,000

<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
21 December 2017